232 related articles for article (PubMed ID: 26603345)
1. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials.
Korkmaz T; Seber S; Basaran G
Crit Rev Oncol Hematol; 2016 Feb; 98():180-8. PubMed ID: 26603345
[TBL] [Abstract][Full Text] [Related]
2. [The molecular biology of epithelial ovarian cancer].
Leary A; Pautier P; Tazi Y; Morice P; Duvillard P; Gouy S; Uzan C; Gauthier H; Balleyguier C; Lhommé C
Bull Cancer; 2012 Dec; 99(12):1161-73. PubMed ID: 23238064
[TBL] [Abstract][Full Text] [Related]
3. The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer.
Menderes G; Black JD; Azodi M
Expert Rev Anticancer Ther; 2016 Sep; 16(9):899-901. PubMed ID: 27477495
[No Abstract] [Full Text] [Related]
4. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
[TBL] [Abstract][Full Text] [Related]
6. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N; Abubaker K; Findlay J; Quinn M
J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
[TBL] [Abstract][Full Text] [Related]
7. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
8. New paradigms in the surgical and adjuvant treatment of ovarian cancer.
Hodeib M; Eskander RN; Bristow RE
Minerva Ginecol; 2014 Apr; 66(2):179-92. PubMed ID: 24848076
[TBL] [Abstract][Full Text] [Related]
9. Epithelial ovarian cancer: a review of current management.
Guppy AE; Nathan PD; Rustin GJ
Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):399-411. PubMed ID: 16149282
[TBL] [Abstract][Full Text] [Related]
10. The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer.
Bookman MA
Ann Oncol; 2010 Oct; 21 Suppl 7():vii211-17. PubMed ID: 20943617
[TBL] [Abstract][Full Text] [Related]
11. Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Seward SM; Winer I
Cancer Metastasis Rev; 2015 Mar; 34(1):5-10. PubMed ID: 25597035
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing clinical trial enrollment among ovarian cancer patients.
Greenwade MM; Moore KN; Gillen JM; Ding K; Rowland MR; Crim AK; Kleis B; Gunderson CC
Gynecol Oncol; 2017 Sep; 146(3):465-469. PubMed ID: 28689668
[TBL] [Abstract][Full Text] [Related]
13. Optimizing treatment in recurrent epithelial ovarian cancer.
Corrado G; Salutari V; Palluzzi E; Distefano MG; Scambia G; Ferrandina G
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1147-1158. PubMed ID: 29086618
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
Rauh-Hain JA; Foley OW; Winograd D; Andrade C; Clark RM; Vargas RJ; Hinchcliff EM; Esselen KM; Horowitz NS; del Carmen MG
Am J Obstet Gynecol; 2015 May; 212(5):600.e1-8. PubMed ID: 25514761
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of advanced ovarian carcinoma: surgery before chemotherapy or chemotherapy before surgery?].
Piura B
Harefuah; 2014 Sep; 153(9):524-6, 558-9. PubMed ID: 25417488
[TBL] [Abstract][Full Text] [Related]
16. Epithelial ovarian cancer.
Ng JS; Low JJ; Ilancheran A
Best Pract Res Clin Obstet Gynaecol; 2012 Jun; 26(3):337-45. PubMed ID: 22281513
[TBL] [Abstract][Full Text] [Related]
17. Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
Petrillo M; Amadio G; Salutari V; Paris I; Di Stefano MG; Ferandina G; Scambia G; Fagotti A
Gynecol Oncol; 2016 Aug; 142(2):231-6. PubMed ID: 27215633
[TBL] [Abstract][Full Text] [Related]
18. Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study.
Wong CN; Wong CN; Liu FS
Taiwan J Obstet Gynecol; 2017 Jun; 56(3):302-305. PubMed ID: 28600037
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients.
Bakrin N; Cotte E; Golfier F; Gilly FN; Freyer G; Helm W; Glehen O; Bereder JM
Ann Surg Oncol; 2012 Dec; 19(13):4052-8. PubMed ID: 22825772
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
Monk BJ; Dalton H; Farley JH; Chase DM; Benjamin I
Crit Rev Oncol Hematol; 2013 May; 86(2):161-75. PubMed ID: 23137764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
